This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The PRESTO study adds to the evidence that noninvasive vagus nerve stimulation (nVNS) is an effective acute treatment for migraine. An established treatment for cluster headache,1 nVNS produced higher pain-free rates than sham stimulation 30 minutes and 1 hour post-treatment, but missed statistical significance at the 2 hours primary endpoint (30.4% vs 19.7%; p = 0.067). Significant results relative to sham stimulation were not achieved for associated symptoms.
Footnotes
See page 166
Author Contributions: RBL/PJG-Drafting/revising the mansucript.
Study funding: No targeted funding reported.
Disclosure: Dr. Richard B. Lipton is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York; receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (PI), RO1 NS082432 (Investigator), 1RF1 AG057531 (Site PI), RF1 AG054548 (Investigator), 1RO1 AG048642 (Investigator), R56 AG057548 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor), 1K01AG054700 (Mentor); receives research support from the Migraine Research Foundation, the National Headache Foundation, Bristol Myers Squibb, Vedanta Research, Boston Scientific, S & L Marx Foundation, Czap Foundation, Novartis, and Allergan; serves on the editorial board of Neurology, is the senior advisor to Headache, and is associate editor to Cephalalgia; has reviewed for the NIA and NINDS; holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr. Reddy's, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta; and receives publishing royalties from Oxford University Press and Baxter Publishing. Dr. Peter J. Goadsby has been a consultant for Alder Biopharmaceuticals, Allergan, Amgen, Autonomic Technologies Inc., Dr Reddy's Laboratories, Eli-Lilly, Electrocore LLC, eNeura Inc., Novartis, Scion, Teva Pharmaceuticals, and Trigemina; has served on the editorial boards of Journal Watch, Up-to-Date, and the Massachusetts Medical Society; has received publishing royalties from Elsevier; holds stock/stock options in Trigemina Inc.; has received personal fees from Oxford University Press, Wolters Kluwer, and MedicoLegal work; has received grants and personal fees from Amgen and Eli-Lilly and Company (outside the submitted work); and holds a patent—Magnetic stimulation for headache—licensed to eNeura without fee. Go to Neurology.org/N for full disclosures.
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
